Phase 2a Trial
The phase 2a Alzheimer’s disease study for LM11A-31 is being conducted in a network of sites based in Sweden, Germany, Austria, the Czech Republic and Spain. As is the case with most drug trials, approximately one-third of the trial participants will be treated with placebo, thus there is no guarantee that participants will receive the drug. Unfortunately, for this study there will be no participation options in the US. Specific sites and contact information is listed on a number of websites including clinicaltrials.gov and the European Union Clinical Trials Registry. Study site directors can provide additional information regarding the logistics of potential participation. We expect the study to take approximately two years to complete. If the phase 2a study is successful, a phase 3 study will be conducted at many additional sites with a number likely to be in the US.